# Treatment of Periprosthetic Joint Infection After Tumor Megaprosthetic Reconstruction: A Narrative Review

## TL;DR

This review explores the challenges of treating joint infections after tumor prosthetic surgery, emphasizing the need for tailored approaches and future research.

## Contribution

The paper provides a comprehensive narrative review of managing periprosthetic joint infections after tumor megaprosthetic reconstruction.

## Key findings

- PJI risk factors include patient, disease, and treatment-related factors.
- Diagnosis requires adapted criteria and combines clinical, serological, imaging, and microbiological methods.
- Two-stage revision is considered the gold standard for chronic PJI cases.

## Abstract

Periprosthetic joint infection (PJI) is a devastating complication, leading to high morbidity and complex management. Reported PJI rates after primary tumor megaprosthetic reconstruction ranged from 5% to 25%, significantly higher than the 0.5% to 2% observed in conventional hip and knee arthroplasty. The management of PJIs after tumor megaprosthetic reconstruction is complex. This narrative review aims to provide a comprehensive and critical summary of the current understanding of PJIs following tumor megaprosthetic reconstruction. It will specifically focus on analyzing the evidence behind risk factors, diagnostic approaches, and treatment outcomes, and will identify persistent knowledge gaps to guide future research and clinical practice.

Purpose: Periprosthetic joint infection (PJI) is a devastating complication following limb salvage surgery with tumor megaprosthetic reconstruction, leading to high morbidity and complex management. Despite advancements in prosthesis design and materials, infection rates are notably higher than in conventional arthroplasty. This narrative review synthesizes current evidence on the etiology, diagnosis, and management of PJIs in this unique setting. Methods: We conducted narrative review of literature from PubMed and Embase using keywords related to PJIs and tumor megaprostheses, aiming to summarize risk factors, diagnostic criteria, pathogen profiles, and treatment outcomes. Results: Key findings indicate that the risk of PJI is multifactorial, involving patient-related, disease-related, and treatment-related factors. Diagnosis relies on a combination of clinical presentation, serological markers, imaging, and microbiological studies, though established criteria for conventional PJI may require adaptation for tumor cases. Treatment strategies include irrigation and debridement (I&D), debridement, antibiotics, implant retention with modular component exchange (DAIR), one-stage or two-stage revision, and amputation. Success rates vary, and optimal management requires a multidisciplinary, individualized approach. However, two-stage revision is considered the gold standard for chronic PJIs. Conclusions: PJIs after tumor megaprosthetic reconstruction presents distinct challenges. Management requires a multidisciplinary, individualized approach. Future research should focus on validated diagnostic criteria for this population, novel anti-biofilm strategies, and standardized treatment protocols.